Benefits
Colonic butyrate delivery vs free butyrate (laboratory gut simulator, not people)
In a Triple-L-SHIME laboratory gut simulator (glassware seeded with stool from three healthy adult male donors, with no people involved), the capsule formulation was 40.9% hydrolyzed in the small intestine with 59.1% reaching the colon (softgel: 48.7% / 51.3%). By contrast, free butyrate (sodium butyrate) is rapidly absorbed in the upper GI and very little reaches the colon — the underlying rationale for using a triglyceride prodrug instead of free butyrate.
Microbiome and inflammation effects (in vitro)
In the same Triple-L-SHIME® + Caco-2/THP1 co-culture model, daily tributyrin increased butyrate production, shifted the bacterial community, with increases reported in Bifidobacterium longum and Akkermansia muciniphila rather than in butyrate-producing species, increased IL-10, decreased TNF-α in the proximal colon while IL-1β, another pro-inflammatory marker, went up there, and protected against inflammation-induced intestinal barrier disruption. Effects emerged later in the treatment period, suggesting longer-term administration matters. All findings are in vitro — human translation is not yet established.
Postbiotic concept
Tributyrin is often marketed as a postbiotic because it delivers butyrate, a bacterial fermentation product, without needing a fiber substrate or live bacteria. Strictly, that label is wrong: the ISAPP consensus definition covers preparations of inanimate microorganisms or their components, and it specifically excludes purified metabolites such as butyrate, which ISAPP says should be called by their chemical names instead. Tributyrin is often suggested for people with low fiber tolerance or low microbial diversity, though no trial has tested whether it helps that group.
Colonocyte energy substrate
Textbook physiology holds that butyrate is the primary energy source for colonocytes, supplying roughly 60 to 70 percent of their energy, which is background about colonic butyrate in general rather than a finding about tributyrin. Adequate colonic butyrate supports normal colonic epithelial cell function. Whether oral tributyrin meaningfully increases colonocyte butyrate availability in humans has not been demonstrated in clinical trials.
Stomach-acid resistance and odorless formulation
The triglyceride form resists gastric acid degradation and is odorless — addressing two practical limitations of free butyrate (sodium butyrate has an unpleasant odor and is degraded/absorbed before reaching the colon). Formulation advantage rather than efficacy claim.
Mechanism of action
Pancreatic lipase hydrolysis to colonic butyrate
The triglyceride structure resists gastric acidity. Pancreatic lipase in the small intestine hydrolyzes tributyrin to release butyrate progressively, allowing a portion to reach the colon. This is the distinguishing pharmacokinetic advantage over free butyrate salts.
HDAC inhibition by butyrate
Butyrate inhibits histone deacetylases (HDACs), modifying gene expression with anti-inflammatory effects in cell and animal models. The HDAC mechanism applies to butyrate generally — not specific to tributyrin.
Tight junction integrity and NF-κB anti-inflammatory effects
Butyrate enhances tight junction protein expression (claudins, occludin, ZO-1) in intestinal epithelium and downregulates NF-κB-mediated inflammation, with corresponding effects reported in Caco-2/THP1 co-cultures.
GPR41 / GPR43 short-chain fatty acid receptor activation
Butyrate activates GPR41 (FFAR3) and GPR43 (FFAR2) on enteroendocrine cells, immune cells, and adipocytes, which in laboratory models modulates GLP-1 and PYY release and immune signaling. That is standard butyrate biology and it has not carried over to tributyrin in people: in a randomized crossover meal study in 12 healthy men, tributyrin produced no rise in GLP-1, PYY, GIP or cholecystokinin, no better than a carrot control, while olive oil and a C8 oil did raise GLP-1.
Clinical trials
Duysburgh C, Verstrepen L, Van Meulebroek L, Marzorati M. Frontiers in Nutrition 2025;12:1712993. A laboratory gut simulator study, not a trial in people.
Not a clinical population. This entry produced no human outcome data.
Duysburgh et al. 2025, Frontiers in Nutrition 12:1712993. No people took part. Upper GI tract simulation + Triple-L-SHIME® gut model with 3 healthy donor microbiomes + Caco-2/THP1 co-cultures. Capsule (300 mg) and softgel (450 mg) CoreBiome® formulations. Capsule: 40.9% small-intestinal hydrolysis, 59.1% colonic delivery. Softgel: 48.7% / 51.3%. Increased butyrate, increased Bifidobacterium longum and Akkermansia muciniphila, neither of them a butyrate producer, increased IL-10, decreased TNF-α, protection from inflammation-induced barrier disruption. In vitro evidence only, pivotal for the ingredient but not human. The study was funded by Compound Solutions, the CoreBiome supplier, and carried out by the contract laboratory ProDigest, which employs all four authors.
Florida State University randomized triple-masked crossover trial, planned 300 mg/day CoreBiome® for 4 weeks in sedentary adults with outcomes including metabolite concentrations, gut permeability, inflammation, sleep, and performance.
Sedentary adults were planned, but the trial was terminated and no participant results were ever reported.
No results exist from this trial. It was terminated for loss of funding before any outcome data was published, so it shows nothing about what CoreBiome does in people. As planned it was a Florida State University randomized triple-masked crossover trial of 300 mg/day CoreBiome for 4 weeks in sedentary adults, with outcomes including metabolite concentrations, gut permeability, inflammation, sleep, and performance. This was the only registered human clinical trial of CoreBiome®.
Heidor R, Ortega JF, de Conti A, Ong TP, Moreno FS. Anticarcinogenic actions of tributyrin, a butyric acid prodrug. Current Drug Targets 2012;13(14):1720-1729. A narrative review of cell and animal work, not a trial.
Not applicable. This is a review of cell and animal studies, not a study in people.
Heidor R et al. 2012, Curr Drug Targets 13:1720-1729. A narrative review of tributyrin research in cancer cell lines and animal models. It is not limited to colorectal cancer. Tributyrin has been given to cancer patients in two early phase I studies, and the larger of them reported no objective tumor responses in 20 people. Nothing here supports taking tributyrin to prevent or treat any disease; this entry exists only so readers are not misled by the preclinical cancer literature.